secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001628280-22-013590
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Q1 net loss widens to $68.1M; cash $838M; LYL797 trial starts
-------------------------------------------------------------------

- GAAP net loss $68.1M vs $55.0M YoY; non-GAAP net loss $50.0M vs $32.3M.
- Cash, equivalents and marketable securities $838M as of March 31, 2022.
- Phase 1 screening started for LYL797 (ROR1 CAR-T) in TNBC/NSCLC; initial data in 2023.
- IND cleared for LYL132 (TCR therapy targeting NY-ESO-1); LYL845 TIL IND on track for H2 2022.
- Appointed Gary Lee, Ph.D., as Chief Scientific Officer to lead research strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828022013590/0001628280-22-013590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828022013590/lyel-20220510.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-013590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer